A proteomic test can predict outcome with chemotherapy versus erlotinib in NSCLC patients.
Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer (NSCLC), but only among patients who are likely to have a poor outcome with the latter treatment type.
Specifically, patients predicted to have poor survival outcomes with epidermal growth factor receptor—tyrosine kinase inhibitors (EGFR–TKI) according to the proteomic test survived a median 3 months longer when treated with chemotherapy than their counterparts who received the EGFR–TKI erlotinib.
By contrast, neither treatment regimen was associated with superior overall survival among patients whose predicted outcomes were good.
Original report: http://bit.ly/1jugCqX
Source: medwire News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More